# Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026 Canonical URL: https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-hold-first-quarter-2026-business-update-conference-call-and-ef5e4a87 Ticker: LUCD Company: Lucid Diagnostics Source: Lucid Diagnostics Published: 2026-04-30 12:31 EST Original Source URL: https://ir.luciddx.com/2026-04-30-Lucid-Diagnostics-to-Hold-First-Quarter-2026-Business-Update-Conference-Call-and-Webcast-on-May-14,-2026 ## Summary Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced... ## Article Body Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026 Conference Call and Webcast at 8:30 AM ET , / PRNewswire / -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Thursday, May 14, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D. , Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath , Lucid's Chief Financial Officer, will discuss the Company's first quarter 2026 financial results. The webcast will be available at the investor relations section of the Company's website at luciddx.com . Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com . About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard ® Esophageal DNA Test , performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device , represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com . SOURCE Lucid Diagnostics For further information: Investor and Media Contact: Matt Riley, Vice President, Investor Relations, PAVmed and Lucid Diagnostics, mjr@pavmed.com ## Recent Company News - 2026-05-14 12:00 EST — [Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: Lucid Diagnostics - 2026-04-30 12:31 EST — [Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-hold-first-quarter-2026-business-update-conference-call-and-ef5e4a87) — Source: Lucid Diagnostics - 2026-04-24 14:23 EST — [Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-announces-closing-of-18-million-underwritten-offering-of-common-stock) — Source: Lucid Diagnostics - 2026-04-23 12:30 EST — [Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-announces-18-million-underwritten-offering-of-common-stock) — Source: Lucid Diagnostics - 2026-04-09 12:01 EST — [Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: Lucid Diagnostics ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)